The transfer of this novel targeted treatment to other cancer types with BRAF alterations has been initiated for different brain tumors including papillary craniopharyngiomas of the sellar region and several clinical trials have been designed to provide evidence of antitumor activity beyond single case reports of treatment response. Here, BRAF is linked to brain neoplasm.